0000899243-22-010987.txt : 20220314
0000899243-22-010987.hdr.sgml : 20220314
20220314213330
ACCESSION NUMBER: 0000899243-22-010987
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220311
FILED AS OF DATE: 20220314
DATE AS OF CHANGE: 20220314
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEKKERS MARIJN E
CENTRAL INDEX KEY: 0001216068
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40097
FILM NUMBER: 22738662
MAIL ADDRESS:
STREET 1: GENERAL ELECTRIC COMPANY
STREET 2: 41 FARNSWORTH STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc.
CENTRAL INDEX KEY: 0001830214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 872652913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (877) 442-5362
MAIL ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20210210
FORMER COMPANY:
FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20201027
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-11
0
0001830214
Ginkgo Bioworks Holdings, Inc.
DNA
0001216068
DEKKERS MARIJN E
C/O GINKGO BIOWORKS HOLDINGS, INC.
27 DRYDOCK AVENUE
BOSTON
MA
02210
1
0
0
0
Class A Common Stock
2022-03-11
4
A
0
1746706
0.00
A
2121666
D
Class A Common Stock
5780364
I
By Novalis LifeSciences Investments I, L.P.
The reporting person was previously granted awards of restricted stock units covering Class A Common Stock, which vest based upon the Issuer's achievement of an event condition (i.e., an underwritten initial public offering or a change in control), subject to additional time based vesting conditions in accordance with the terms of the award. On March 11, 2022, the Compensation Committee of the Issuer's Board of Directors, after consideration of the completion of the initial business combination, modified the event condition, resulting in the immediate vesting of 1,390,938 restricted stock units for which the time based vesting requirements had been satisfied as of December 31, 2021 and the issuance of a corresponding number of shares of Class A Common Stock. The remaining restricted stock units will continue to vest in accordance with the terms of the award.
The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
/s/ Karen Tepichin, Attorney-in-fact
2022-03-14